Company intelligence / Profile preview

Ardeagen Corporation

Ownership: Private
Development stage: Other

Overview

As of February 2021, Ardeagen was collaborating with BioNova Pharmaceuticals to develop up to three ADCs for oncology/hematology indications. The team has experience with ADC technologies and has been involved in bringing several ADCs to market, including Adcetris and Trodelvy.

Therapeutic areas: Oncology
Modalities: Antibody Drug Conjugates (ADCs)
Industry: Biotech

Partnerships

BioNova Pharmaceuticals (strategic collaboration announced February 22, 2021)

Beyond the preview

Go deeper on Ardeagen Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ardeagen Corporation.

Explore the full profile